Prostate cancer awareness month emphasizes early screening

September is recognized as Prostate Cancer Awareness Month, highlighting the critical importance of early detection and regular health screenings for men. Medical experts emphasize that prostate cancer often presents no early symptoms, making proactive testing essential.

In Turkey, data from GLOBOCAN 2022 indicates 17,274 new cases were recorded in 2022, making it the second most common cancer in men after lung cancer. Experts note that while a high Prostate-Specific Antigen (PSA) level can indicate cancer, it can also be caused by benign enlargement or infection, requiring a comprehensive clinical evaluation.

Screening recommendations vary based on risk factors. The American Cancer Society suggests discussions about screening for average-risk men around age 50, while those at higher risk—such as African American men or those with a first-degree relative diagnosed before age 65—should consider starting at age 45. Some guidelines suggest even earlier intervention for those with specific genetic risks like BRCA2.

Personal accounts from patients underscore that early diagnosis can lead to manageable outcomes, even in advanced stages. In New Zealand, statistics show one in eight men will be diagnosed with prostate cancer in their lifetime, though many cases are slow-growing and treatable.